Cell News and Research

RSS

Master gene linked to childhood brain tumor

The master gene Math1 is involved in the genesis of the most common childhood brain tumor, medulloblastoma, said researchers from Baylor College of Medicine (www.bcm.edu) in a report in the current issue of the journal Science.

4 Dec 2009

GIND scientists identify drug treatments that can normalize neuron development in AD

Scientists at the Gladstone Institute of Neurological Disease (GIND) have discovered that two main causes of AD amyloid-beta (Aβ) peptides and apolipoprotein E4 (apoE4) impair the growth of new neurons born in adult brains. What is more, they have identified drug treatments that can normalize the development of these cells even in the presence of Aβ or apoE4. The findings are described in two separate papers published in the current issue of Cell Stem Cell.

4 Dec 2009

Study on Helicos BioSciences' single molecule sequencing technology published

Helicos BioSciences Corporation today announced the publication of a landmark study by Dr. Bradley Bernstein of the Massachusetts General Hospital describing the use of Helicos’ single molecule sequencing technology for the performance of genome-wide, epigenomic experiments using minute amounts of nucleic acid.

4 Dec 2009

ISIS-FXIRx and ISIS-SMNRx included in Isis Pharmaceuticals' development pipeline

Isis Pharmaceuticals, Inc. announced today that it has added two new drugs to its development pipeline, ISIS-FXIRx and ISIS-SMNRx.

4 Dec 2009

ISTODAX included in the updated NCCN Clinical Practice Guidelines in Oncology

Gloucester Pharmaceuticals announced today that ISTODAX® (romidepsin) has been included in the updated National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology™ as a suggested systemic treatment option for patients with mycosis fungoides and Sézary syndrome—two of the most common types of cutaneous T-cell lymphoma (CTCL).

4 Dec 2009

Instacare announces initial parallel marketing strategy for its cell phone centric products

Instacare Corp., a leading provider of life-saving prescription drugs, home testing products for the chronically ill, a leading fulfillment provider of direct to patient diabetes programs and a leading developer of e-health technology and revolutionary cell phone centric technologies and products announced today its intent to file multiple updated and enhanced patent and trademark applications covering its cell phone centric technologies with the United States Patent and Trademarks Office.

4 Dec 2009

ZIOPHARM Oncology begins public offering of common stock

ZIOPHARM Oncology, Inc. announced today that it intends to offer shares of its common stock and warrants to purchase shares of its common stock in a public offering. JMP Securities LLC and Rodman & Renshaw, LLC are acting as co-lead managers for the offering.

4 Dec 2009

Shorter amyloid fibres more toxic than longer counterparts, says study

A major discovery is challenging accepted thinking about amyloids - the fibrous protein deposits associated with diseases such as Alzheimer's and Parkinson's - and may open up a potential new area for therapeutics.

4 Dec 2009

Text messaging technology has important implications for public health initiatives, finds study

A recent study conducted by the Center for Connected Health, a division of Partners HealthCare, found that text messaging is an innovative, low-cost and effective way to improve the daily use of sunscreen, and this technology may have important implications for larger-scale public health initiatives.

4 Dec 2009

Researchers discover new strategy against invasive parasite

Researchers at Albert Einstein College of Medicine of Yeshiva University have discovered a possible strategy against an invasive parasite that infects more than a quarter of the world's population, including 50 million Americans.

4 Dec 2009

Update on European commercial launch of MuGard for oral mucositis provided

ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), today provided an update on its European commercial launch of MuGard, an FDA approved treatment for oral mucositis, a debilitating side effect of radiation treatment and chemotherapy.

4 Dec 2009

NIH approves new stem cell lines for research

The National Institutes of Health announced approval of embryonic stem cell lines for federally funded research. The Washington Post reports the decision is "opening the way for millions of taxpayer dollars to be used to conduct research that was put off-limits by President George W. Bush.

3 Dec 2009

Allos Therapeutics to launch the COMPLETE registry for patients with PTCL

Allos Therapeutics, Inc. today announced the launch of an international registry designed to address the urgent need to better understand treatment patterns and outcomes for patients with peripheral T-cell lymphoma (PTCL). The registry, known as COMPLETE (Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment), is a global observational study that will enroll patients with newly-diagnosed PTCL and obtain data regarding longitudinal treatment patterns and outcomes.

3 Dec 2009

First Edition: December 3, 2009

Today's headlines indicate that Senate leaders may have broken their stalemate regarding the pending, Democratic-backed health reform legislation -- clearing the way today for votes on amendments.

3 Dec 2009

China's SFDA initiates quality investigation of Simcere Pharmaceutical Group subsidiary's rabies vaccine

Simcere Pharmaceutical Group, a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today reported that China's State Food and Drug Administration ("SFDA") has initiated a comprehensive investigation into quality issues regarding human use rabies vaccine (vero cell) manufactured by Simcere's subsidiary Jiangsu Yanshen Biological Technology Stock Co., Ltd. ("Jiangsu Yanshen").

3 Dec 2009

PEG polymer may prevent GI injury during cancer radiotherapy

A non-absorbed, oral co-polymer therapy under development by Midway Pharmaceuticals demonstrated the ability to protect against damage to healthy gastrointestinal tissues and to prevent lethal bacterial infections in animal models of radiation damage.

3 Dec 2009

Sperm from men with NOA and OA capable of producing embryos

It has been thought that men with non-obstructive azoospermia (NOA), a lack of sperm in the semen not caused by an obstruction within the reproductive system, are poor candidates for IVF. Now, researchers writing in the open access journal Reproductive Biology and Endocrinology have shown that sperm from men with NOA and obstructive azoospermia (OA) are equally capable of producing embryos.

3 Dec 2009